Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 8,630 KRW
Change Today +30.00 / 0.35%
Volume 85.0K
000020 On Other Exchanges
Symbol
Exchange
Korea SE
As of 2:28 AM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

dongwha pharm co ltd (000020) Snapshot

Open
8,460
Previous Close
8,600
Day High
8,740
Day Low
8,460
52 Week High
04/13/15 - 9,140
52 Week Low
08/8/14 - 4,905
Market Cap
241.0B
Average Volume 10 Days
195.0K
EPS TTM
177.00
Shares Outstanding
27.9M
EX-Date
12/29/14
P/E TM
48.8x
Dividend
80.00
Dividend Yield
0.93%
Current Stock Chart for DONGWHA PHARM CO LTD (000020)

Related News

No related news articles were found.

dongwha pharm co ltd (000020) Related Businessweek News

No Related Businessweek News Found

dongwha pharm co ltd (000020) Details

Dongwha Pharm Co., Ltd. manufactures and exports pharmaceutical products worldwide. The company offers pharmaceutical products in the areas of gastrointestinal, cardiovascular, respiratory, orthopedic, neuropsychologic, gentio-urinary, gynecologic, dermatologic, ophthalmic, dental, hepatic, and other diseases, as well as ear, nose, and throat diseases. It also provides ethnical and OTC products, quasi-drugs, health subsidiary foods, food-drinks, and cosmetics. In addition, the company develops Milican Injection, a radiopharmaceutical drug for the treatment of hepatocellular carcinoma. Dongwha Pharm Co., Ltd. was founded in 1897 and is headquartered in Seoul, South Korea.

Founded in 1897

dongwha pharm co ltd (000020) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

dongwha pharm co ltd (000020) Key Developments

Dongwha Pharm Co.,Ltd., Annual General Meeting, Mar 27, 2015

Dongwha Pharm Co.,Ltd., Annual General Meeting, Mar 27, 2015., at 10:00 Korea Standard Time. Location: Indeed Giheung-gu, Top 35 beongil 71 Pharmaceutical Institute assimilation gasong. Agenda: To consider sales report, the financial statements for the year ended December 31, 2014; and to approve director remuneration limit.

Dong Wha Pharmaceuticals and Kyung Hee University Sign Technology Transfer Agreement

Dong Wha Pharmaceuticals and Kyung Hee University have signed an agreement to transfer technologies used to develop treatments for inflammatory and immune diseases including inflammatory vowel disease. The technology transfer is related to two natural complex extracts developed by Professor Kim Dong-hyun, Pharmacology School of Kyung Hee University, which are effective to treat inflammatory bowel diseases. The treatment using the two natural extracts has been proven its superior efficacy compared to existing compounds in a number of animal model tests. It is expected to demonstrate similar anti-inflammatory effects on local inflammation versus 5-aminosalicylic acid strain medicines, and further stimulates immune regulation throughout the body after absorption.

Dongwha Pharm Co.,Ltd., Special/Extraordinary Shareholders Meeting, Oct 31, 2013

Dongwha Pharm Co.,Ltd., Special/Extraordinary Shareholders Meeting, Oct 31, 2013., at 10:00 Korea Standard Time. Location: gu, Yongin-si. Agenda: To consider the election of Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
000020:KS 8,630.00 KRW +30.00

000020 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 000020.
View Industry Companies
 

Industry Analysis

000020

Industry Average

Valuation 000020 Industry Range
Price/Earnings 49.4x
Price/Sales 1.1x
Price/Book 1.1x
Price/Cash Flow 32.4x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DONGWHA PHARM CO LTD, please visit www.dong-wha.co.kr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.